ESC 365 - Antithrombotic therapy in patients with transcatheter aortic valve implantation: Balancing risks with benefits.

Open Access

Antithrombotic therapy in patients with transcatheter aortic valve implantation: Balancing risks with benefits.

Session: Optimising oral anticoagulation for atrial fibrillation patients undergoing cardiac interventions in 2021: From evidence to practice

Topic: Atrial Fibrillation (AF)

Speaker: Professor J. ten Berg (Nieuwegein, NL)

Sponsored by Bristol Myers Squibb and Pfizer

Event: ESC Congress 2021 - The Digital Experience

Congress Presentation

Add to my library

About the speaker

Professor Jurrien M ten Berg

St Antonius Hospital, Nieuwegein (Netherlands (The))

20 presentations

1 follower

3 more presentations in this session

Welcome: The shifting risk/benefit balance of non-vitamin K antagonist oral anticoagulants for non-valvular atrial fibrillation and cardiac interventions.

Speaker: Professor I. Van Gelder (Groningen, NL)

Building the evidence base for cardiac interventions in non-valvular atrial fibrillation.

Speaker: Professor R. Lopes (Durham, US)

Panel Q&A.

Access the full session

Optimising oral anticoagulation for atrial fibrillation patients undergoing cardiac interventions in 2021: From evidence to practice

Speakers: Professor J. ten Berg, Professor I. Van Gelder, Professor R. Lopes

About the event

ESC Congress 2021 - The Digital Experience

27 August - 30 August 2021

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources